Carregant...
Phase II Randomized Study of Enzastaurin (LY317615) for Lung Cancer Prevention in Former Smokers
BACKGROUND: Chemoprevention for lung cancer with neutraceuticals or anti-inflammatory agents has had mixed clinical benefit. Novel targeted agents hold the promise of greater efficacy and selectivity. Here, we evaluated enzastaurin, a selective PKC-β inhibitor with antiproliferative and proapoptotic...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3578040/ https://ncbi.nlm.nih.gov/pubmed/23065656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27836 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|